Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › DBVT

DBV Technologies

DBVT Lead: NDA Submitted 9 Biotech Distilled articles ↓ 36 filings & releases ↓ Cash $166M (Sep 30, 2026) ↓ 9 verdicts ↓ 2 timing quotes ↓
Immunology Protein

Market cap $3.29B 314.4M shares (10-Q, Oct 26, 2026) × $10.45 close Nov 6, 2026

Most recent annual filing: 2026-03-15

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Viaskin Peanut Toddlers 1-3yo BLA2027Viaskin Peanut Toddlers 1-3yo BLA, 2027, material
  2. Toddler BLA ages 1-3 filing2027Toddler BLA ages 1-3 filing, 2027, material
  3. Fareva Amboise factory FDA decisionFeb 1, 2027Fareva Amboise factory FDA decision, Feb 1, 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (2 active programs)

Technology platforms

Viaskin

Epicutaneous immunotherapy platform delivering biologically active compounds through intact skin via an epicutaneous patch; targets Langerhans cells to activate immune system without systemic allergen exposure; focus on food allergies in children and autoimmune inflammatory diseases.

Discontinued (1)

Capital (as filed)

Cash
$166M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$51.5M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$166M cash, runway into the third quarter of 2027 per the update of Oct 28, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on DBV Technologies, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2025-12-22 Buy core DBV Technologies (DBVT): Scientific Due Diligence VITESSE Phase 3 data scientifically validates the Viaskin platform with strong efficacy and safety, cash is solved via warrant exercises, and the de-risked asset is an M&A target; short-term supply overhang from Bpifrance selling is a technical, not fundamental, concern.
  2. 2026-03-28 Buy core UPDATE: DBV Technologies (DBVT) - FDA Hits Fast Forward FDA waiving the COMFORT Children safety study accelerates the BLA timeline by a full year, commercial manufacturing is being locked in via an 8-year FAREVA deal, and the company is funded through the anticipated FDA decision date.
  3. 2026-06-29 Buy core UPDATE: DBV Technologies (DBVT) - The BLA Slips a Quarter The BLA slip to Q3 2026 is a CMC presentation reformat, not a data problem; the science thesis is intact and the filing acceptance decision ~60 days post-submission is now the true binary, but the thesis has not broken.
  4. 2026-07-16 Watch UPDATE: DBV Technologies (DBVT) - The Warning Letter Buried in the 10-Q An FDA cGMP warning letter at Fareva Amboise, DBV's sole patch manufacturer with no backup, turns filing acceptance into a two-way binary and flattens the risk/reward enough to step to the sidelines pending remediation.
  5. 2026-07-17 Watch UPDATE: DBV Technologies (DBVT) - The ATM Refills, One Day After the Warning Letter The $150M ATM refresh one day after the warning letter disclosure, with 'manufacturing expansion' leading the use-of-proceeds, confirms the remediation cost is real and adds dilution risk on top of the existing factory overhang.
  6. 2026-07-31 Watch UPDATE: DBV Technologies (DBVT) - They Used the ATM. Fast. Consuming one-third of the $150M ATM in 13 days signals management is sizing for a material manufacturing remediation bill; the filing acceptance decision remains the event that resolves the thesis.
  7. 2026-08-07 Watch UPDATE: DBV Technologies (DBVT) - Who Bought the $50M RA Capital's 13G reveals the $50M ATM tranche was a negotiated block to a single specialist healthcare fund, reducing overhang fears, but the Fareva Amboise warning letter and filing acceptance binary remain unresolved.
  8. 2026-09-30 Watch UPDATE: DBV Technologies (DBVT) - The BLA Is In. The Clock Is Running. BLA submission was delivered inside the Q3 window, repairing some management credibility, but the Fareva Amboise warning letter still makes filing acceptance a two-way binary and no upgrade is warranted until the FDA weighs in.
  9. 2026-10-29 Watch UPDATE: DBV Technologies (DBVT) - Going Concern, a Toddler Slip, and a Factory Roadmap Going-concern language and a toddler BLA slip to 2027 worsen the outlook, but the first dated and measurable Fareva Amboise remediation plan and Palforzia's market exit partially offset; filing acceptance in ~one month remains the unresolved binary.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (2 quotes from 2 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (36)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jun 2, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)